May round-up of pharma/biotech M&A activity

3 June 2016

Deals, rumors and resistance to takeovers have been abundant across the pharma sphere this month as activity continues to pick up following the pause in dealmaking in the first quarter of the year, and in the wake of March's failed $160 billion mega merger between US pharma giant Pfizer (NYSE: PFE) and Ireland-incorporated Allergan (NYSE: AGN).

Increasingly aggressive attempts by French pharma major Sanofi (Euronext: SAN) to press ahead with a $9.3 billion takeover of Medivation (Nasdaq: MDVN), and the board of the US biotech firm resisting the bid, has been responsible for weeks of posturing and speculation. The early days of June could be crucial in determining the outcome of it all.

Biggest deal:

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK